Efficacy and Safety of Parecoxib vs. Indomethacin in Preventing Post-ERCP Pancreatitis

Phase 2

Not yet recruiting

• Conditions: Pancreatitis, Acute; Cholangiopancreatography, Endoscopic Retrograde
• Interventions: Drug: Parecoxib Sodium; Drug: Indomethacin suppository

• Registration Number: NCT06623513
• Lead Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Brief Summary

This study aims to evaluate the efficacy and safety of parecoxib versus indomethacin in preventing post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). It is a single-center, prospective, randomized, controlled, exploratory trial. Participants will be randomly assigned to receive either parecoxib or indomethacin as a preventive treatment. The primary endpoint is to compare the efficacy of the two drugs in reducing the incidence of PEP. Secondary endpoints include the incidence of moderate to severe PEP and post-ERCP-related adverse events. This study will systematically assess the efficacy and safety of both drugs, providing preliminary data for future larger confirmatory trials.

Detailed Description

Not available

Study Timeline

• Status Verified: 2024-09
• Study First Submitted: 2024-09-27
• Study First Submitted QC: 2024-09-29
• Last Update Submitted: 2024-09-29
• Study Start: 2024-10-01
• Study First Posted: 2024-10-02
• Last Update Posted: 2024-10-02
• Primary Completion: 2026-09-30
• Study Completion: 2026-09-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Age between 18 and 80 years.
• Patients scheduled to undergo ERCP for conditions such as common bile duct stones, benign or malignant biliary strictures, cholangitis, suspected biliary tumors, unexplained jaundice, or pancreas divisum.

Exclusion Criteria

• Previous papillectomy.
• Previous endoscopic sphincterotomy (EST) without planned pancreatic duct intervention.
• Simple biliary stent removal or replacement without planned pancreatic duct intervention.
• Biliary-duodenal fistula, post-biliary-duodenal anastomosis, or post-biliary-jejunal anastomosis.
• Malignant tumor of the pancreatic head.
• Currently or recently (within 1 week) suffering from acute pancreatitis.
• Current or recent (within 1 week) use of NSAIDs.
• Recent (within 2 weeks) or within 4 weeks prior to surgery, gastrointestinal bleeding or peptic ulcers.
• History of significant adverse reactions to NSAIDs.
• Renal insufficiency (creatinine clearance < 30 mL/min).
• Moderate to severe hepatic impairment (Child-Pugh score ≥ 7).
• Severe cardiovascular or cerebrovascular disease.
• Patients with psychiatric disorders.
• Pregnant or breastfeeding patients.
• Patients without a rectum.
• Patients unwilling or unable to provide informed consent.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Parecoxib Group	Parecoxib Sodium	-
Indomethacin Group	Indomethacin suppository	-

Primary Outcome Measures

Name	Time	Method
Incidence of Post-ERCP Pancreatitis (PEP)	24 hours after ERCP procedure.	The primary outcome is the proportion of patients who develop post-ERCP pancreatitis. PEP is characterized by new or worsened abdominal pain, elevated serum amylase levels (≥3 times the upper normal limit).

Secondary Outcome Measures

Name	Time	Method
Incidence of Moderate to Severe PEP	At discharge (up to 30 days)	The severity of PEP will be classified according to the Cotton consensus and the revised Atlanta classification.
Incidence of Hyperamylasemia	3 and 24 hours after ERCP procedure	Hyperamylasemia is defined as a serum amylase level greater than three times the upper limit of normal, without the onset of new abdominal pain or worsening of existing pain.
Post-Procedure Discomfort Symptoms	Baseline (pre-procedure), 3 hours post-procedure, 6 hours post-procedure, 12 hours post-procedure, 24 hours post-procedure, 48 hours post-procedure, 72 hours post-procedure, and at discharge (up to 30 days)	Definition: Post-ERCP discomfort symptoms primarily include abdominal pain, nausea, vomiting, sore throat, abdominal bloating, dizziness, and headache. To comprehensively assess the severity of these symptoms, the study will utilize the Symptom Severity Index (SSI) to quantify and analyze patient-reported symptoms.; Assessment Method: Each symptom will be self-assessed by the patient using the Numeric Rating Scale (NRS), a self-assessment tool, and verified by the study staff. The score ranges from 0 to 10, where 0 represents no symptoms, and 10 represents the most severe symptoms.; Scoring Weights: The final score for each symptom will be calculated by multiplying the symptom score by its respective weight. The total symptom score will be the sum of all weighted scores, with a maximum score of 100.
Bleeding, Perforation, Cholangitis, Cardiac Adverse Events, Renal Adverse Events	3 hours post-procedure, 6 hours post-procedure, 12 hours post-procedure, 24 hours post-procedure, 48 hours post-procedure, 72 hours post-procedure, and at discharge (up to 30 days)	Symptom-driven detection methods will be used to evaluate adverse events. The severity of bleeding, perforation, and cholangitis will be assessed according to the Cotton criteria.